Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Primary structure of human 11-cis retinol dehydrogenase and organization and chromosomal localization of the corresponding gene.
It is demonstrated that the primary structure of human 11-cis retinol dehydrogenase is highly conserved with 91% identity to the bovine enzyme.
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
- T. Frebourg, Svetlana Bajalica Lagercrantz, M. Hietala
- Medicine, BiologyEuropean Journal of Human Genetics
- 26 May 2020
The expansion of the LFS concept to a wider cancer predisposition syndrome designated heritable TP53-related cancer (hTP53rc) syndrome is justified and whole-body MRI (WBMRI) allows early detection of tumours in variant carriers.
Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells
This study identified salinomycin (SAL) as a potent inhibitor of autophagy and cytotoxic agent effective on several cancer cell lines under conditions of transient and chronic acidosis and reported that the ability of SAL to inhibit mammosphere formation from CSC-like cells was dramatically enhanced in acidic conditions.
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
- Å. Fransson, D. Glaessgen, J. Alfredsson, K. Wiman, S. Bajalica-Lagercrantz, N. Mohell
- Biology, MedicineJournal of Ovarian Research
- 14 May 2016
Analysis of the anticancer effects of APR-246 in combination with conventional chemotherapy in primary cancer cells isolated from ascitic fluid from 10 ovarian, fallopian tube, or peritoneal cancer patients suggests that combination treatment with APR- 246 and DNA-damaging drugs could significantly improve the treatment of patients with TP53 mutant HGS cancer.
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
BRCA1/2 mutation prevalence in unselected breast cancer patients was 1.8%.
Expression of the BCL6 gene in the pre- and postnatal mouse.
- S. Bajalica-Lagercrantz, F. Piehl, F. Farnebo, C. Larsson, J. Lagercrantz
- BiologyBiochemical and biophysical research…
- 18 June 1998
The results show that bcl6 expression is not confined only to organs of the lymphatic system, such as spleen and thymus, and may be active as a regulator of gene transcription in many different cell types, including epithelial and nerve cells.
Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome
The evidence base for cancer surveillance in this guideline are limited, emphasising the need for prospective evaluation of the effectiveness of surveillance in the PHTS population.
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
The Molecular Tumor Board Portal (MTBP), a clinical decision support system that unifies the analysis of sequencing results across seven European comprehensive cancer centers under the umbrella of the Cancer Core Europe (CCE) network, is developed.
Germline TP53 Testing in Breast Cancers: Why, When and How?
- D. Evans, E. Woodward, S. Bajalica-Lagercrantz, Carla Oliveira, T. Frebourg
- Medicine, BiologyCancers
- 1 December 2020
Germline TP53 testing should be performed before treatment and offered systematically only to patients with invasive breast cancers occurring before 31 years of age, and women presenting with breast cancer after 46, without suggestive personal or familial history, should not be tested for TP53.